XTRA:BAYNPharmaceuticals
Is It Too Late To Consider Bayer (XTRA:BAYN) After A 59.8% One-Year Surge?
Investors may be asking whether Bayer at €38.05 is still offering value after a strong run, or if most of the opportunity has already been priced in.
The stock has returned 59.8% over the last year, while the 7-day and 30-day returns of a 1.2% decline and a 4.1% decline hint at some recent hesitation, with year-to-date performance roughly flat at 0.1%.
Recent news around Bayer has focused on its ongoing transformation as a large pharmaceuticals and life sciences group and how that is being...